Ermakov S et al. |
A significant association exists between receptor tyrosine kinase-like orphan receptor 2 gene variants and the OPG/RANKL ratio in human plasma. |
2012 |
Osteoporos Int |
pmid:22057548
|
Hampson G et al. |
Effects of dietary improvement on bone metabolism in elderly underweight women with osteoporosis: a randomised controlled trial. |
2003 |
Osteoporos Int |
pmid:12904840
|
Dobnig H et al. |
Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients. |
2006 |
Osteoporos Int |
pmid:16435076
|
Kananen K et al. |
Serum osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) concentrations in allogeneic stem cell transplant-recipients: a role in bone loss? |
2006 |
Osteoporos Int |
pmid:16437190
|
Xie H et al. |
Omentin-1 exerts bone-sparing effect in ovariectomized mice. |
2012 |
Osteoporos Int |
pmid:21755404
|
Jiang SD et al. |
Effects of spinal cord injury on osteoblastogenesis, osteoclastogenesis and gene expression profiling in osteoblasts in young rats. |
2007 |
Osteoporos Int |
pmid:17036173
|
Khosla S et al. |
Correlates of osteoprotegerin levels in women and men. |
2002 |
Osteoporos Int |
pmid:12086350
|
Dovio A et al. |
Variations along the 24-hour cycle of circulating osteoprotegerin and soluble RANKL: a rhythmometric analysis. |
2008 |
Osteoporos Int |
pmid:17703272
|
Zhang Y et al. |
Study of the mechanisms by which Sambucus williamsii HANCE extract exert protective effects against ovariectomy-induced osteoporosis in vivo. |
2011 |
Osteoporos Int |
pmid:20414641
|
Pennisi P et al. |
Low bone density and abnormal bone turnover in patients with atherosclerosis of peripheral vessels. |
2004 |
Osteoporos Int |
pmid:14661073
|
Niu YB et al. |
The beneficial effect of Radix Dipsaci total saponins on bone metabolism in vitro and in vivo and the possible mechanisms of action. |
2012 |
Osteoporos Int |
pmid:22535190
|
Aubin JE and Bonnelye E |
Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption. |
2000 |
Osteoporos Int |
pmid:11193242
|
Zhao HY et al. |
The influence of Lys3Asn polymorphism in the osteoprotegerin gene on bone mineral density in Chinese postmenopausal women. |
2005 |
Osteoporos Int |
pmid:15782282
|
Belaya ZE et al. |
Serum extracellular secreted antagonists of the canonical Wnt/β-catenin signaling pathway in patients with Cushing's syndrome. |
2013 |
Osteoporos Int |
pmid:23358608
|
Mangiafico RA et al. |
Increased augmentation index and central aortic blood pressure in osteoporotic postmenopausal women. |
2008 |
Osteoporos Int |
pmid:17676381
|
Nakashima A et al. |
Osteoprotegerin and bone mineral density in hemodialysis patients. |
2006 |
Osteoporos Int |
pmid:16604298
|
Hamed AA and Fayad JN |
Presence of otosclerosis and paget lesions in the same temporal bone. |
2009 |
Otol. Neurotol. |
pmid:19779387
|
Kuczkowski J et al. |
[Molecular control of bone resorption in chronic otitis media with cholesteatoma]. |
2010 Jul-Aug |
Otolaryngol Pol |
pmid:20873097
|
Cervellati C et al. |
Higher Urinary Levels of 8-Hydroxy-2'-deoxyguanosine Are Associated with a Worse RANKL/OPG Ratio in Postmenopausal Women with Osteopenia. |
2016 |
Oxid Med Cell Longev |
pmid:26635910
|
Songia P et al. |
Identification of Patients Affected by Mitral Valve Prolapse with Severe Regurgitation: A Multivariable Regression Model. |
2017 |
Oxid Med Cell Longev |
pmid:28261377
|
Heitzer E et al. |
IL-7, IL-18, MCP-1, MIP1-β, and OPG as biomarkers for pain treatment response in patients with cancer. |
2012 Nov-Dec |
Pain Physician |
pmid:23159968
|
Satoh K et al. |
Tumor necrosis factor-related apoptosis-inducing ligand and its receptor expression and the pathway of apoptosis in human pancreatic cancer. |
2001 |
Pancreas |
pmid:11590320
|
Pietrapertosa AC et al. |
Osteoprotegerin and RANKL in the pathogenesis of osteoporosis in patients with thalassaemia major. |
2009 |
Panminerva Med |
pmid:19352306
|
Gulseren A et al. |
Evaluation of weekly risedronate treatment in postmenopausal women with osteoprotegerin. |
2011 |
Panminerva Med |
pmid:21659972
|
D'Amore M et al. |
Receptor activator of NF(Kappa)B ligand/osteoprotegerin (RANKL/OPG) system and osteopontin (OPN) serum levels in a population of apulian postmenopausal women. |
2006 |
Panminerva Med |
pmid:17215793
|
Michou L et al. |
[Molecular analysis of Paget's disease of bone]. |
2007 Apr-May |
Pathol. Biol. |
pmid:16884862
|
Ikeda T et al. |
Hepatocellular carcinoma with osteoclast-like giant cells: possibility of osteoclastogenesis by hepatocyte-derived cells. |
2003 |
Pathol. Int. |
pmid:12828610
|
Quan J et al. |
Molecular pathways involved in crosstalk between cancer cells, osteoblasts and osteoclasts in the invasion of bone by oral squamous cell carcinoma. |
2012 |
Pathology |
pmid:22406484
|
Won KY et al. |
RANK signalling in bone lesions with osteoclast-like giant cells. |
2011 |
Pathology |
pmid:21532526
|
Levidou G et al. |
TRAIL and osteoprotegerin (OPG) expression in bladder urothelial carcinoma: correlation with clinicopathological parameters and prognosis. |
2013 |
Pathology |
pmid:23277172
|
Chan MH et al. |
Specific biochemical markers of bone metabolism and cytokine study confirm the diagnosis of malignant infantile osteopetrosis at birth using cord blood sample. |
2005 |
Pathology |
pmid:15875734
|
Ishii R et al. |
High serum values of soluble CD154, IL-2 receptor, RANKL and osteoprotegerin in Langerhans cell histiocytosis. |
2006 |
Pediatr Blood Cancer |
pmid:16358318
|
Skordis N et al. |
Hormonal dysregulation and bones in thalassaemia--an overview. |
2008 |
Pediatr Endocrinol Rev |
pmid:19337163
|
Angelopoulos NG et al. |
Markers of bone metabolism in eugonadal female patients with beta-thalassemia major. |
2007 Oct-Nov |
Pediatr Hematol Oncol |
pmid:17786784
|
Rianthavorn P et al. |
Trabecular bone volume and osteoprotegerin expression in uremic rats given high calcium. |
2010 |
Pediatr. Nephrol. |
pmid:20676692
|
Wasilewska A et al. |
Serum RANKL, osteoprotegerin (OPG), and RANKL/OPG ratio in nephrotic children. |
2010 |
Pediatr. Nephrol. |
pmid:20602239
|
Siomou E et al. |
Serum osteoprotegerin, RANKL and fibroblast growth factor-23 in children with chronic kidney disease. |
2011 |
Pediatr. Nephrol. |
pmid:21479768
|
Ketteler M et al. |
"Missing" inhibitors of calcification: general aspects and implications in renal failure. |
2005 |
Pediatr. Nephrol. |
pmid:15549415
|
Swolin-Eide D et al. |
The novel bone alkaline phosphatase B1x isoform in children with kidney disease. |
2006 |
Pediatr. Nephrol. |
pmid:16932897
|
Rosso DA et al. |
Elevated serum levels of the decoy receptor osteoprotegerin in children with Langerhans cell histiocytosis. |
2006 |
Pediatr. Res. |
pmid:16439593
|
Bargman R et al. |
High- and low-dose OPG-Fc cause osteopetrosis-like changes in infant mice. |
2012 |
Pediatr. Res. |
pmid:22926546
|
Vidal K et al. |
Osteoprotegerin in human milk: a potential role in the regulation of bone metabolism and immune development. |
2004 |
Pediatr. Res. |
pmid:15155868
|
Honsawek S et al. |
Relationships between OPG, RANKL, bone metabolism, and bone mineral density in biliary atresia. |
2009 |
Pediatr. Surg. Int. |
pmid:19184056
|
Petersson M et al. |
Oxytocin stimulates proliferation of human osteoblast-like cells. |
2002 |
Peptides |
pmid:12126740
|
Bartold PM et al. |
Mechanisms and control of pathologic bone loss in periodontitis. |
2010 |
Periodontol. 2000 |
pmid:20403105
|
Nagasawa T et al. |
Roles of receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoprotegerin in periodontal health and disease. |
2007 |
Periodontol. 2000 |
pmid:17214836
|
Wang AY |
Vascular and other tissue calcification in peritoneal dialysis patients. |
2009 |
Perit Dial Int |
pmid:19270239
|
Nemec K and Schubert-Zsilavecz M |
[Future therapies for metabolic bone diseases. New concepts and targets]. |
2001 |
Pharm Unserer Zeit |
pmid:11715689
|
Treuheit MJ et al. |
Inverse relationship of protein concentration and aggregation. |
2002 |
Pharm. Res. |
pmid:12033388
|
Miyaji Y et al. |
Novel comb-shaped PEG modification enhances the osteoclastic inhibitory effect and bone delivery of osteoprotegerin after intravenous administration in ovariectomized rats. |
2012 |
Pharm. Res. |
pmid:22729371
|